On account of the lack of predictive biomarkers of toxicity, we investigated whether polymorphisms of genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with outcomes of adjuvant capecitabine in patients with early stage gastrointestinal cancers.
Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine / Roberto, M., Romiti, A., Botticelli, A., Mazzuca, F., Lionetto, L., Gentile, G., Paris, I., Falcone, R., Bassanelli, M., DI PIETRO, F.R., Onesti, C.E., Anselmi, E., Macrini, S., Simmaco, M., Marchetti, P.. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - STAMPA. - 73:2(2017), pp. 157-164. [10.1007/s00228-016-2160-8]
Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine
ROBERTO, MICHELA;ROMITI, ADRIANA;BOTTICELLI, ANDREA;MAZZUCA, FEDERICA;GENTILE, Giovanna;FALCONE, ROSA;BASSANELLI, MARIA;DI PIETRO, FRANCESCA ROMANA;ONESTI, CONCETTA ELISA;ANSELMI, ELISABETTA;MACRINI, SERENA;SIMMACO, Maurizio;MARCHETTI, PAOLO
2017
Abstract
On account of the lack of predictive biomarkers of toxicity, we investigated whether polymorphisms of genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with outcomes of adjuvant capecitabine in patients with early stage gastrointestinal cancers.| File | Dimensione | Formato | |
|---|---|---|---|
|
Roberto_Evaluation_2017.pdf
solo utenti autorizzati
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
738.75 kB
Formato
Adobe PDF
|
738.75 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
